Source: Virtual Congress 2021 – Burden and epidemiology of COVID-19



Rating:

Share or cite this content

Citations should be made in the following way:
S. Ottaviani (Pavia (PV), Italy), I. Ferrarotti (Pavia (PV), Italy), A. Balderacchi (Pavia (PV), Italy), V. Barzon (Pavia (PV), Italy), A. Corino (Pavia (PV), Italy), A. De Silvestri (Pavia (PV), Italy), D. Piloni (Pavia (PV), Italy), F. Mariani (Pavia (PV), Italy), A. Corsico (Pavia (PV), Italy). COVID-19 infection in Severe Alpha 1-antitrypsin deficiency: looking for a rationale. 918

Member's Comments

No comment yet.

Related content which might interest you: Alpha 1-antitrypsin deficiency Source: Breathe 2008; 4: 377-380 Year: 2008 Diagnosing alpha 1-antitrypsin deficiency: how to improve the current algorithm Source: Eur Respir Rev 2015; 24: 52-57 Year: 2015 Alpha 1 - antitrypsin deficiency: diagnosis and treatment Source: Virtual Congress 2021 – Alpha 1 - antitrypsin deficiency: diagnosis and treatment Year: 2021 Alpha 1-Antitrypsin deficiency (AATD) in patients with ARDS consequent to SARS-CoV-2 infection. Source: Virtual Congress 2021 – COVID – 19: treatments and predictive factors Year: 2021 A case report of alpha 1-antitrypsin deficiency in a six-month infant Source: Eur Respir J 2004; 24: Suppl. 48, 228s Year: 2004 Phase I safety investigation of an aerosolized, recombinant alpha 1-antitrypsin in subjects with alpha 1-antitrypsin deficiency Source: Eur Respir J 2004; 24: Suppl. 48, 228s Year: 2004 Targeted screening programmes in COPD: how to identify individuals with alpha 1-antitrypsin deficiency Source: Eur Respir Rev 2015; 24: 40-45 Year: 2015 Monitoring disease progression in severe Alpha1 antitrypsin deficiency Source: Virtual Congress 2020 – Clinical and basic pharmacology for COPD Year: 2020 Clinical features of alpha one antitrypsin deficiency in COPD Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management Year: 2012 Reduction in incidence of exacerbations in patients with alpha 1 antitrypsin deficiency (A1ATD) treated with concentrates of alpha 1 antitrypsin (A1AT): REXA study Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Long-term experience in the treatment of alpha 1-antitrypsin deficiency: 25 years of augmentation therapy Source: Eur Respir Rev 2015; 24: 46-51 Year: 2015 Severe alpha-1-antitrypsin deficiency (A1ATD) caused by Q0Ourém mutation: A clinical characterization Source: Annual Congress 2010 - Genetics of obstruction Year: 2010 Circulating polymers in ?1-antitrypsin deficiency Source: Eur Respir J 2014; 43: 1501-1504 Year: 2014 Identification of a novel SERPINA-1 mutation causing alpha-1 antitrypsin deficiency in a patient with severe dyspnea Source: International Congress 2016 – Molecular targets in pulmonary disease Year: 2016 Diagnosing alpha-1 antitrypsin deficiency in Romania - first 1000 cases tested Source: Virtual Congress 2020 – Asthma and COPD: How genetic and environment influences its developement? Year: 2020 Has cardiopulmonary exercise testing a role in detecting early emphysema in alpha 1-antitrypsin deficiency? Source: Eur Respir J 2001; 18: Suppl. 33, 84s Year: 2001 Alpha-1 antitrypsin deficiency – a potentially fatal disease Source: International Congress 2017 – Rare and common genetic variants of common and rare airway diseases Year: 2017 Alpha-1 antitrypsin deficiency and spontaneous pneumothorax: just a coincidence? Source: International Congress 2017 – Rare and common genetic variants of common and rare airway diseases Year: 2017 Alpha-1 antitrypsin deficiency and pulmonary morbidity in patients with primary immunodeficiency disease: A single center experience Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Smoke exposure as a determinant of autoantibody titre in alpha 1-antitrypsin deficiency and COPD Source: Eur Respir J 2011; 37: 32-38 Year: 2011